Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Mette S. van Ramshorst"'
Autor:
Tessa G Steenbruggen, Gabe S. Sonke, Erik van Werkhoven, Sabine C. Linn, Sabine Siesling, Marleen Kok, Vincent O. Dezentjé, Mette S. van Ramshorst
Publikováno v:
European journal of cancer, 135, 66-74. Elsevier
European Journal of Cancer, 135, 66-74. Elsevier Limited
European Journal of Cancer, 135, 66-74. Elsevier Limited
Background Recommendations on adjuvant chemotherapy in pT1N0M0 triple-negative breast cancer (TNBC) differ among international guidelines owing to lack of randomized trial data. We evaluated associations of adjuvant chemotherapy with a long-term outc
Autor:
Sabine C. Linn, Gabe S. Sonke, I.A.M. Mandjes, Inge Kemper, Carolien H. Smorenburg, Aafke H. Honkoop, Erik van Werkhoven, Jacqueline M. Stouthard, Irma M. Oving, Mette S. van Ramshorst, Vincent O. Dezentjé
Publikováno v:
The Breast. 29:153-159
Background The addition of pertuzumab to neoadjuvant trastuzumab-based chemotherapy improves pathologic complete response rates in HER2-positive breast cancer. However, increased toxicity has been reported with the addition of pertuzumab, and this ma
Autor:
Gabe S. Sonke, Maartje van Seijen, Mette S. van Ramshorst, Esther H. Lips, Jelle Wesseling, Tessa G Steenbruggen, Liselore Maria Janssen, Erik van Werkhoven, Marie-Jeanne T. F. D. Vrancken Peeters
Publikováno v:
Clinical cancer research, 25(16), 4985-4992. American Association for Cancer Research Inc.
Purpose: In breast cancer, pathologic complete response (pCR) to neoadjuvant systemic therapy (NST) is associated with favorable long-term outcome. Trastuzumab emtansine as additional adjuvant therapy improves recurrence-free survival of patients wit
Autor:
Gwen M. H. E. Dackus, Margriet van der Heiden-van der Loo, Mette S. van Ramshorst, Sabine C. Linn, Gabe S. Sonke
Publikováno v:
Breast Cancer Research and Treatment, 158(2), 361. Springer New York
The prognosis of patients with stage II–III Human Epidermal growth factor Receptor 2 (HER2)-positive breast cancer has significantly improved since the addition of trastuzumab to (neo-)adjuvant chemotherapy. Several reports have shown that small (
Autor:
Suzana C Teixeira, Bas B. Koolen, Jelle Wesseling, Marie-Jeanne T. F. D. Vrancken Peeters, Emiel J. Th. Rutgers, Gabe S. Sonke, Sjoerd Rodenhuis, Renato A. Valdés Olmos, Mette S. van Ramshorst, Kenneth E. Pengel, Kenneth G. A. Gilhuijs, Wouter V. Vogel
Publikováno v:
Cancer Imaging, Vol 17, Iss 1, Pp 1-8 (2017)
Cancer imaging, 17(1). e-med
Cancer Imaging, 17(1). e-med
Cancer Imaging
Cancer imaging, 17(1). e-med
Cancer Imaging, 17(1). e-med
Cancer Imaging
Background 18F-FDG PET/CT can monitor metabolic activity in early breast cancer during neoadjuvant systemic therapy (NST), but it is unknown if the metabolic breast and axillary response differ. We evaluated the correlation between metabolic breast a